|
Patient characteristics: early disease |
|
| Characteristic |
n (%) |
|
|
|
| Menopausal status |
|
|
|
|
| Premenopausal |
4 (25) |
|
|
|
| Postmenopausal |
12 (75) |
|
|
|
| Unknown |
0 (0) |
|
|
|
| Tumor size |
|
|
|
|
| pT1 |
3 (19) |
|
|
|
| pT2 |
10 (62) |
|
|
|
| pT3 |
3 (19) |
|
|
|
| Lymph node status |
|
|
|
|
| Node-negative |
6(38) |
|
|
|
| Node-positive |
10 (62) |
|
|
|
| Histologic grade |
|
|
|
|
| Grade 1 |
1 (6) |
|
|
|
| Grade 2 |
11 (69) |
|
|
|
| Grade 3 |
4 (25) |
|
|
|
| ER/PR tumor status |
|
|
|
|
| Positive |
11 (69) |
|
|
|
| Negative |
4 (25) |
|
|
|
| Unknown |
1 (6) |
|
|
|
| HER2 tumor status |
|
|
|
|
| Positivea |
3 (19) |
|
|
|
| Negative |
12 (75) |
|
|
|
| Unknown |
1 (6) |
|
|
|
| EGFR tumor status |
|
|
|
|
| Positive |
3 (19) |
|
|
|
| Negative |
9 (56) |
|
|
|
| Unknown |
4 (25) |
|
aA score +3 or fluorescence in situ hybridization positive. EGFR, epidermal growth factor receptor; ER, estrogen receptor; HER, human epidermal growth factor receptor; PR, progesterone receptor. | |
Kallergi et al. Breast Cancer Research 2008 10:R80 doi:10.1186/bcr2149 |
|